相关实验视频
Updated: May 7, 2026

08:49
Models of Bone Metastasis
Published on: September 4, 2012
42.3K
对转移性骨瘤的zoledronic酸给药时间的影响
Manabu Watanabe1, Hiroyuki Tsuchie2, Hiroyuki Nagasawa2
1Department of Orthopedic Surgery, Akita University Graduate School of Medicine, Akita, Japan; mwatanabe@med.akita-u.ac.jp.
In vivo (Athens, Greece)
|June 27, 2025
概括
在乳腺癌骨转移模型中,早期服用佐列龙酸 (ZA) 显著减少骨破坏和瘤生长. 在注射瘤细胞之前或在注射瘤细胞时开始ZA治疗会产生最好的结果.
科学领域:
- 在瘤学瘤学.
- 药理学 药理学是指药理学的学科.
- 骨生物学 骨生物学
背景情况:
- 乳腺癌骨转移显著影响患者的生存率和生活质量.
- 佐勒多尼酸 (ZA) 是一种用于管理骨转移的双酸盐.
- 在这种情况下,ZA的最佳时间尚不清楚.
研究的目的:
- 在乳腺癌骨转移的临床前小鼠模型中研究不同ZA施用时间的疗效.
- 为了确定早期的ZA干预是否会改善与骨破坏和瘤进展相关的结果.
主要方法:
- 通过将E0771细胞注射到股骨中,建立了乳腺癌骨转移的小鼠模型.
- ZA在不同的时间点进行:在 (-1w) 之前1周,同时 (0w),在 (1w) 后1周,在 (2w) 瘤细胞接种后2周.
- 骨损坏,瘤体积,瘤生长和亡被评估使用微型计算机断层扫描和组织学分析.
主要成果:
- 与对照组相比,所有接受ZA治疗的组都显示骨损坏率显著降低 (p<0.05).
- -1w组的骨损伤率明显低于1w和2w组的骨损伤率 (p<0.05).
- 与对照组相比,1w和0w组的瘤生长明显抑制 (p<0.05),瘤缩没有显著差异.
结论:
- 早些时候服用ZA与更有效地抑制骨破坏有关.
- 在瘤细胞注射之前或与瘤细胞注射同时开始ZA治疗,可以增强其在骨转移中的抗瘤原生作用.
相关概念视频
Bone Disorders
Aging and its effect on bone remodeling is the most common cause of bone disorders. In young and healthy people, bone deposition and resorption happen at an equal rate to maintain optimal bone health.
Bone deposition is also affected by the levels of sex hormones like estrogen and testosterone that promote osteoblast activity and bone matrix synthesis. When the level of these hormones decreases due to aging, it causes a reduction in bone deposition. As a result, bone resorption by osteoclasts...
Bone deposition is also affected by the levels of sex hormones like estrogen and testosterone that promote osteoblast activity and bone matrix synthesis. When the level of these hormones decreases due to aging, it causes a reduction in bone deposition. As a result, bone resorption by osteoclasts...
Time Course of Drug Effect
The progression of a drug's impact can be analyzed by examining both the concentration-time course and the effect-time course. The concentration-time course is determined by the drug's half-life and is influenced by factors such as its pharmacokinetics, including absorption, distribution, metabolism, and elimination. The effect of the drug is often related to its concentration in the plasma and is calculated using the maximum drug effect and the plasma concentration that generates 50 percent of...
Drug Distribution: Tissue Binding
Upon entering the systemic circulation, drugs can distribute into the interstitial and intracellular fluid of various tissue cells. This distribution is facilitated by the binding of drugs to different cellular components within tissues, which may lead to drug accumulation in specific areas. Drugs bound to tissue components serve as reservoirs that release free drugs back into the system, prolonging the drug's overall action. However, this accumulation can also result in local toxicity.
For...
For...
Chronopharmacokinetics: Circadian Rhythms and Influence on Drug Response
Circadian rhythms are cyclic changes that are crucial in plasma drug concentrations. Various standard circadian parameters, including core body temperature, heart rate, and other cardiovascular factors, directly impact disease states and the therapeutic response to drug therapy.
The time of drug administration is an important factor to consider, as it can influence the toxic dose of a drug. For example, a study conducted by Prins et al. in 1997 examined the effects of the timing of...
The time of drug administration is an important factor to consider, as it can influence the toxic dose of a drug. For example, a study conducted by Prins et al. in 1997 examined the effects of the timing of...
Therapeutic Drug Monitoring: Affecting Factors
Therapeutic Drug Monitoring (TDM) is the clinical practice of measuring specific drug levels in a patient's blood or body tissues to manage and optimize therapy. TDM is crucial for drugs with narrow therapeutic windows, like warfarin and phenytoin, where incorrect doses can lead to treatment failure or severe side effects. This monitoring ensures the dosage administered is within a safe and effective range. The factors affecting therapeutic drug monitoring include:Patient-Specific Factors:a.
Pharmacokinetic–Pharmacodynamic Relationship: Duration of Dose-Effect Relationship
For drugs producing a quantal response, onset occurs when plasma concentration reaches a minimum effective level (Cmin). The drug's action duration depends on how long the plasma concentration remains above Cmin.Two primary factors influence this duration: dose size and the rate of drug removal from the action site. Both depend on the drug's redistribution to poorly perfused tissues and elimination processes. A larger dose promotes rapid onset and prolongs the effect's duration.Consider a...

